Normal Absolute Monocyte Count in Combination with Normal/High Absolute Lymphocyte Count at the Time of Relapse is Associated with Improved Survival in Patients with Early Relapsed Acute Myeloid Leukemia

References

• Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105(9):3420–3427. doi:10.1182/blood-2004-08-2977.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083. doi:10.1182/blood.V96.13.4075.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479–485. doi:10.1182/blood-2003-05-1686.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–1311. doi:10.1182/blood.v98.5.1302.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062. doi:10.1056/NEJM199909303411407.
   PubMed Web of Science ®Google Scholar
• Burnett AK. Acute myeloid leukemia: treatmentof adults under 60 years. Rev Clin Exp Hematol. 2002;6(1):26–45. doi:10.1046/j.1468-0734.2002.00058.x.
   PubMedGoogle Scholar
• Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002;43(9):1715–1727. doi:10.1080/1042819021000006529.
   PubMed Web of Science ®Google Scholar
• Estey E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14(3):476–479. doi:10.1038/sj.leu.2401568.
   PubMed Web of Science ®Google Scholar
• Weltermann A, Fonatsch C, Haas O, Greinix H, Kahls P, Mitterbauer G, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia. 2004;18(2):293–302. doi:10.1038/sj.leu.2403243.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Martin W, Sauerland C, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. 1990;4(3):184–188.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7(8):1071–1080. doi:10.1200/JCO.1989.7.8.1071.
   PubMed Web of Science ®Google Scholar
• Thalhammer F, Geissler K, Jäger U, Kyrle P, Pabinger I, Mitterbauer M, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol. 1996;72(4):216–222. doi:10.1007/s002770050163.
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol. 2018;181(1):27–37. doi:10.1111/bjh.15077.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569. doi:10.1200/JCO.2009.23.8329.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889. doi:10.1038/ni.1937.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Am J Hematol. 2014;89(4):423–428. doi:10.1002/ajh.23661.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–1050. doi:10.1086/591969.
   PubMed Web of Science ®Google Scholar
• Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;18(4):600–607. doi:10.1016/j.bbmt.2011.08.007.
   PubMed Web of Science ®Google Scholar
• DeCook L, Thoma M, Huneke T, Johnson N, Wiegand R, Patnaik MM, et al. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant. 2013;48(5):708–714. doi:10.1038/bmt.2012.211.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D’Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):297–299. doi:10.1038/bmt.2015.244.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436. doi:10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2013;31(2):65–71. doi:10.1002/hon.2019.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53(4):575–580. doi:10.3109/10428194.2011.637211.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Kay S, Sarid N, Kohan P, Braunstein R, Rotman R, et al. Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. Leuk Res. 2013;37(10):1222–1228. doi:10.1016/j.leukres.2013.07.017.
   PubMed Web of Science ®Google Scholar
• Feng J, Zhang W, Wu J, Gao S, Ye H, Sun L, et al. Effect of initial absolute monocyte count on survival outcome of patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma. 2016;57(11):2548–2554. doi:10.3109/10428194.2016.1166491.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49(9):1745–1751. doi:10.1080/10428190802226425.
   PubMed Web of Science ®Google Scholar
• De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer. 2008;112(2):407–415. doi:10.1002/cncr.23168.
   PubMed Web of Science ®Google Scholar
• Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol. 2008;141(6):792–798. doi:10.1111/j.1365-2141.2008.07123.x.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol. 2012;95(2):143–148. doi:10.1007/s12185-011-0993-6.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, Pileri S. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
   PubMedGoogle Scholar
• O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 2.2013. J Natl Compr Canc Netw. 2013;11(9):1047–1055. doi:10.6004/jnccn.2013.0127.
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Sánchez F, Subirá M, Hidalgo A, Sierra J. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the seattle, french, and strasbourg prognostic indexes. Am J Hematol. 2009;84(9):571–578. doi:10.1002/ajh.21488.
   PubMed Web of Science ®Google Scholar
• Shin S-J, Roh J, Kim M, Jung MJ, Koh YW, Park C-S, et al. Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma. Korean J Pathol. 2013;47(6):526. doi:10.4132/KoreanJPathol.2013.47.6.526.
   PubMedGoogle Scholar
• Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant H odgkin lymphoma. Br J Haematol. 2012;157(3):321–330. doi:10.1111/j.1365-2141.2012.09067.x.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97(2):262–269. doi:10.3324/haematol.2011.050138.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88(2):181–186. doi:10.1038/sj.bjc.6600724.
   PubMed Web of Science ®Google Scholar
• Nelson DS. Immunity to infection, allograft immunity and tumour immunity: parallels and contrasts. Transplant Rev. 1974;19:226–254. doi:10.1111/j.1600-065x.1974.tb00134.x.
   PubMed Web of Science ®Google Scholar